uBriGene Cellinfinity In Vivo CAR-T Partnership

uBriGene and Cellinfinity BIO Partner to Advance In Vivo CAR-T Therapies for Solid Tumors

uBriGene Enables FDA IND Clearance for GT307 TIL Therapy

uBriGene Supports FDA IND Clearance of Next-Generation Gene-Edited TIL Therapy GT307 Through Integrated Cell Therapy CDMO Manufacturing

LVV Turbo™: uBriGene’s New GMP Lentiviral Vector Platform with UltraCell™ Integration

uBriGene Launches LVV Turbo™ – Its Next-Generation GMP Lentiviral Vector Manufacturing Platform – and announces a Strategic Partnership with Syenex for integration of its UltraCell™ Technology

uBriGene–Circurna Partnership Accelerates Circular RNA/LNP Therapeutics

uBriGene Biosciences and Circurna Announce Strategic Partnership to Accelerate Development and Manufacturing of Circular RNA/LNP Therapeutics

uBriGene v2 RNA-LNP iPSC Kit PBMCs

uBriGene Unveils V2.0 RNA-LNP iPSC Reprogramming Kit Optimized for PBMCs and Hard-to-Reprogram Cells

Clinical iPSC Banks Released to Advance Cell Therapy

uBriGene Launches Clinical iPSC Banks to Accelerate Regenerative Medicine and Cell Therapy Development

Drug Master File for iPSC Reprogramming mRNA-LNP Kit

Faster Clinical Translation and Commercialization of Therapies Derived From iPSC Technology

Clinical Application in Ophthalmology Passed

Assisted Clinical Application of Gene Therapy in Ophthalmology of Innostellar Accepted by NMPA

Clinical Application for Hemophilia B Accepted

Assisted Clinical Application of Gene Therapy for Hemophilia B of Vitalgen Accepted by NMPA

IND Application Approval

Correcting visual impairment: VGR-R01 project IND application accepted by Center for Drug Evaluation